Friday, January 18, 2013 1:33:21 PM
Posted by Zach Kirkland on Jan 15th, 2013 // No Comments
Zacks reaffirmed their neutral rating on shares of Abiomed (NASDAQ: ABMD) in a research note released on Tuesday morning. They currently have a $13.00 price target on the stock.
ABMD has been the subject of a number of other recent research reports. Analysts at Wunderlich reiterated a buy rating on shares of Abiomed in a research note to investors on Thursday, November 29th. They now have a $29.00 price target on the stock. Separately, analysts at Piper Jaffray reiterated an overweight rating on shares of Abiomed in a research note to investors on Wednesday, November 28th. They now have a $18.00 price target on the stock. Finally, analysts at Raymond James initiated coverage on shares of Abiomed in a research note to investors on Friday, November 9th. They set a market perform rating on the stock.
Five equities research analysts have rated the stock with a buy rating, two have given an overweight rating, two have given a hold rating, one has assigned an underweight rating, and one has given a sell rating to the company. The company currently has an average rating of overweight and an average price target of $19.50.
Shares of Abiomed traded down 1.06% during mid-day trading on Tuesday, hitting $12.19. Abiomed has a one year low of $11.80 and a one year high of $26.17. The stock’s 50-day moving average is currently $13.32. The company has a market cap of $470.9 million and a P/E ratio of 36.45.
Abiomed last announced its earnings results on Thursday, November 1st. The company reported $0.20 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.05 by $0.15. The company had revenue of $37.40 million for the quarter, compared to the consensus estimate of $37.47 million. The company’s quarterly revenue was up 26.9% on a year-over-year basis. On average, analysts predict that Abiomed will post $0.34 earnings per share for the current fiscal year.
Abiomed, Inc. is a provider of medical devices in circulatory support and offers a continuum of care in heart recovery to acute heart failure patients.
To view Zacks’ full report, visit www.zacks.com
________________________________________________________
http://www.jagsreport.com/2013/01/abiomed-stock-rating-reaffirmed-by-zacks-abmd/
ABMD
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM